

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

ALL APPROVED INDICATIONS OF AKESO'S 5 MARKETED DRUGS INCLUDED IN THE MOST RECENT NRDL

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the most recent National Reimbursement Drug List (the “**NRDL**”) (2025) released by China's National Healthcare Security Administration has been updated to include all the approved indications of the Company's 5 marketed innovative drugs, namely 開坦尼[®] (cadonilimab, PD-1/CTLA-4), 依達方[®] (ivonescimab, PD-1/VEGF), ANIKORA[®] (penpulimab, PD-1), 伊喜寧[®] (ebronucimab, PCSK9) and 愛達羅[®] (ebdarokimab, IL-12/IL-23). The most recent 2025 NRDL will become effective on January 1, 2026.

開坦尼[®] (cadonilimab, PD-1/CTLA-4) for the treatment of recurrent or metastatic cervical cancer that has failed platinum-based chemotherapy has been successfully renewed, and the new indications of first-line treatment of locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma and first-line treatment of persistent, recurrent or metastatic cervical cancer have been included in the 2025 NRDL.

依達方[®] (ivonescimab, PD-1/VEGF) for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (“**NSCLC**”) progressed after EGFR TKI has been successfully renewed, and the new indication of first-line treatment of PD-L1-positive (TPS≥1%) NSCLC has been included in the 2025 NRDL.

ANIKORA[®] (penpulimab, PD-1) is co-developed by the Company with Sino Biopharmaceutical Limited (stock code: 1177.HK) together with its subsidiaries. Penpulimab has been included in the 2025 NRDL for the treatment of second-line or above classical Hodgkin lymphoma (cHL), the first-line treatment for locally advanced or metastatic squamous NSCLC, second-line or above nasopharyngeal carcinoma (“NPC”), and first-line recurrent or metastatic NPC.

伊喜寧[®] (ebronucimab, PCSK9) has been included in the 2025 NRDL for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolaemia.

愛達羅[®] (ebdarokimab, IL-12/IL-23) has been included in the 2025 NRDL for the treatment of moderate to severe plaque psoriasis.

The Company is committed to bringing more first-in-class and best-in-class treatment therapies to patients while continuously enhancing their accessibility and affordability. We will deepen our presence across major therapeutic areas and actively facilitate the inclusion of more innovative drugs and new indications in the NRDL, thereby expanding access to a greater number of patients.

Note: Please refer to the 2025 NRDL for the detailed description of the indications mentioned in this announcement.

By order of the Board

Akeso, Inc.

Dr. XIA Yu

Chairwoman and executive director

Hong Kong, December 7, 2025

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive directors, Mr. XIE Ronggang as non-executive director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.